Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab.

被引：0
|
作者：
Pluta, John [1 ]
Qian, Lu [2 ]
D'Andrea, Kurt [1 ]
Duan, Chunzhe [3 ]
Weathers, Benita [1 ]
Wind-Rotolo, Megan [4 ]
Kanetsky, Peter [5 ]
Nathanson, Katherine [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Roche Holding AG, Shanghai, Peoples R China
[4] Bristol Myers Squib, New York, NY USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1352
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
    Schindler, Katja
    Harmankaya, Kaan
    Kuk, Deborah
    Mangana, Joanna
    Michielin, Olivier
    Hoeller, Christoph
    Dummer, Reinhard
    Pehamberger, Hubert
    Wolchok, Jedd D.
    Postow, Michael Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Immune related adverse events and their treatment in melanoma patients receiving ipilimumab.
    Cabanillas, Gerardo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab
    Mian, Idrees
    Yang, Ming
    Zhao, Hui
    Shah, Mohsin
    Diab, Adi
    Shannon, Vickie
    Patel, Anisha
    Amaria, Rodabe Navroze
    Giordano, Sharon Hermes
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Tirumani, Sree Harsha
    Ramaiya, Nikhil H.
    Keraliya, Abhishek
    Bailey, Nancy D.
    Ott, Patrick A.
    Hodi, F. Stephen
    Nishino, Mizuki
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1185 - 1192
  • [5] Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
    Maloney, Anna
    Giobbie-Hurder, Anita
    Fogarasi, Miklos C.
    Ott, Patrick Alexander
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan Leigh
    Buchbinder, Elizabeth Iannotti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
    Pan, Catherina X.
    Liu, Mofei
    Lau, Charles B.
    Lau, William C.
    Kim, Daniel Y.
    Saberi, Shahin A.
    Rowley, Rachael
    Kanwar, Ruhi
    Giobbie-Hurder, Anita
    Leboeuf, Nicole R.
    Nambudiri, Vinod E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 826 - 829
  • [7] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [8] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [9] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
    Abdel-Wahab, Noha
    Diab, Adi
    Yu, Robert K.
    Futreal, Andrew
    Criswell, Lindsey A.
    Tayar, Jean H.
    Dadu, Ramona
    Shannon, Vickie
    Shete, Sanjay S.
    Suarez-Almazor, Maria E.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 1939 - 1949
12345